Abstract:Liver dysfunction during pregnancy can result in adverse pregnancy outcomes. In particular, intrahepatic cholestasis of pregnancy (ICP) increases the risk of stillbirth, while hepatitis B virus (HBV) infection raises the likelihood of developing ICP.1 Despite extensive research, the molecular pathways underlying ICP are not fully understood, and early predictive biomarkers for ICP are still unavailable. Here, we conducted a comparative analysis of plasma cell-free RNA (cfRNA) from ICP (N = 74) or HBV (N = 40) patients and healthy pregnant women (N = 171) to explore the biological processes involved in ICP and HBV infection (Supporting Information Figure S1). We identified cfRNA biomarkers to predict ICP before the onset of symptoms, demonstrating the potential clinical applications of cfRNA in liver diseases. The detailed methods are described in Supporting Information. Nineteen ICP patients with a total bile acids (TBA) concentration of more than 10 μmol/L (ICP_TBA > 10 group) and 55 patients with normal TBA levels (TBA < 10 μmol/L, pre-ICP group) at sampling time were included in the ICP group (Figure 1A). The average diagnosis time of patients in the ICP_TBA > 10 group was 10.89 gestational weeks, which was significantly earlier than that of the pre-ICP group (33.20 gestational weeks) (p = 1.05E-10). The detailed clinical information of ICP patients is summarized in Supporting Information Table S1. Differentially abundant genes (DAGs) analysis identified 34 genes with altered abundance in the plasma of ICP patients (Figure 1B, Supporting Information Figure S2A and Table S2). Some DAGs are involved in transmembrane transport, biosynthesis and metabolism (Figure 1C). Gene set enrichment analysis (GSEA) of mRNA and enrichment analysis of differentially abundant miRNAs (DA-miRNAs) showed that pathways related to immune response, cell junction, extracellular matrix organization, biosynthesis and metabolism, transmembrane transport and coagulation were enriched among genes found to be more abundant in patients with ICP, which reflects the known pathogenesis of ICP (Figure 1D and Supporting Information Figure S2B).2, 3 Single-sample GSEA (ssGSEA) analysis found that most of the pathways related to liver function were only significantly increased in the pre-ICP group but not in the early-diagnosed ICP group, consistent with the differences in clinical liver transferases, implying the heterogeneity between these two groups (Figure 1E and Supporting Information Table S1). Ten samples with positive HBeAg and 30 samples with negative HBeAg were included in the HBV group (Figure 2A). The detailed clinical information of HBV patients is summarized in Supporting Information Table S3. HBV RNA can be detected in 28 (70%) HBV samples and the HBeAg-positive samples presented a higher abundance than the HBeAg-negative samples (Figure 2B). Seven samples were assembled successfully and determined the HBV genotype (Supporting Information Figure S3A). Their sequencing coverage was uniform, avoiding technical errors in sequencing (Supporting Information Figure S3B & C). DAG analysis revealed 125 genes with altered abundance in HBV patients including well-established liver damage biomarkers (Figure 2C, Supporting Information Figure S4A and Table S2).4 The DAGs annotation and GSEA showed that molecular changes of HBV were associated with liver function and cell apoptosis, and these pathways were more significant in HBeAg-positive samples (Figure 2D-F). The enrichment pathway of DA-miRNA target genes is similar to that of the mRNA GSEA result (Supporting Information Figure S4B-C). Among the DAGs, DCTN3, PROESR3, SCD, SLC7A2 and hsa-miR-4443 also increased their abundance in the ICP patients, suggesting a shared molecular alteration in the pathogenesis of HBV and ICP (Supporting Information Table S2). Meanwhile, pathways related to biosynthesis and metabolism, transmembrane transport and complement and coagulation cascades were enriched in both HBV and pre-ICP groups, indicating a shared mechanism of HBV and ICP. We next investigated the feasibility of using cfRNA as a non-invasive tool for assessing liver health. Only one DAG in ICP was liver-specific, while 18 (21%) DA-mRNAs and 5 (18%) DA-miRNAs were liver-specific in HBV, and these genes were upregulated in both HBV and ICP (Figure 3A-C). Additionally, the liver and hepatocyte-specific signature increases in the HBV and pre-ICP groups and the hepatocyte score were positively correlated with alanine aminotransferase, triglyceride, γ-glutamyl transpeptidase and HBV RNA level (Figure 3D-F and Supporting Information Figure S5). Elevated hepatocyte scores from samples with liver cancer further confirmed that hepatocyte signatures are a robust indicator to assess liver health status (Figure 4G).5, 6 The placental and fetal-specific signatures were also investigated. However, no significant alteration was observed except for the fetal liver lymphoid cell (Supporting Information Figure S6), possibly due to the scarcity of fetal signals in early pregnancy and the low TBA concentration. To assess whether plasma cfRNA signatures could identify mothers at risk of ICP, we built a machine learning model using samples from the pre-ICP group and healthy pregnant women. Samples were split into training and validation sets according to the time of blood collection (Figure 4A). A multi-split method with the least absolute shrinkage and selection operator and random forest algorithms was used to select stable features. A gradient boosting machine with seven-fold cross-validation was applied to construct predictive models using mRNA, miRNA and lncRNA, respectively (Figure 4A and Supporting Information Figure S7A). Five mRNA genes (ABCA2, SLC7A2, PXK, RNF141 and FCHO2) were finally selected to construct the model (Figure 4B and Supporting Information Figure S7B). PXK and FCHO2 have been reported to be associated with alkaline phosphatase, aspartate aminotransferase and total cholesterol levels from the genome-wide association studies.7-9 The predictive model using mRNA obtained an AUROC of 0.80 and an accuracy of 0.81 in the validation set (Figure 4C&D), which is comparable with the model using clinical features.10 The model can be applied to ICP risk stratification after being validated by a large multi-center population, complementing the efforts based on clinical data. Eight miRNAs were selected to construct the model, but the AUROC is 0.54 in the validation set (Supporting Information Figure S7C and Table S4). LncRNA cannot produce stable features to train a model after multi-split iterations. In conclusion, we demonstrated that ICP pathophysiology-related changes were identified from plasma cfRNAs in early pregnancy. These changes were distinct in patients with early- and late-diagnosed ICP, with the latter showing similar changes to HBV carriers, implicating different biological processes that drive the underlying pathophysiology of these subtypes of ICP. Additionally, plasma cfRNAs provided a non-invasive means to early identify women at risk for ICP during pregnancy, which could help guide the precision management of pregnancy. We are grateful to the participants for supporting this study. We thank Dr. Jianming Zeng (University of Macau), and all the members of his bioinformatics team, and biotrainees, for generously sharing their experience and codes. The authors declare that they have no competing interest. This work was supported by the research grant from the sub-project of the National Key R&D Program (2022YFC2703702, 2021YFC2701002), National Natural Science Foundation of China (Nos. 81971344, 82171677, 82192864, 82088102 and 81901495), the Shanghai Municipal Commission of Science and Technology Program (22S31901500, 23ZR1408000, 21Y21901002), Shanghai Municipal Commission of Health and family planning (202140110), and CAMS Innovation Fund for Medical Sciences (2019-I2M-5-064), Collaborative Innovation Program of Shanghai Municipal Health Commission (2020CXJQ01), Clinical Research Plan of SHDC (SHDC2020CR1008A), Shanghai Clinical Research Center for Gynecological Diseases (22MC1940200), Shanghai Urogenital System Diseases Research Center (2022ZZ01012) and Shanghai Frontiers Science Research Center of Reproduction and Development. The plasma cfRNA data that support the findings of this study have been deposited into the Genome Sequence Archive for Human Database with accession numbers HRA003387. Plasma cfRNA data from samples with liver cancer and healthy subjects were downloaded from the Gene Expression Omnibus database with accession numbers GSE182824, GSE174302 and GSE142987. The code of cfRNA alignment and quantification is available at https://github.com/wonderful1/PALM-Seq-cfRNA. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:We propose a fully convolutional dense network (FCDN) model1, 2 to predict preeclampsia (PE) with circulating cell-free RNA (cfRNA).3-5 The Individual Risk Score (IRS) output of the proposed FCDN model contributes to the literature on consistently monitoring the risk of PE, evaluating the effect of prophylactic treatments, and providing accurate as well as rapid screening and diagnosis of PE in populous developing countries with a high incidence of PE, such as China. PE is a pregnancy-specific hypertensive disorder and leads to 10.2 deaths per 100 000 pregnancies,6-8 reaming the second death cause of pregnant women in China. Diagnoses of PE are still regularly missed or delayed and predicting PE in early gestation remains challenging. The trained network is designed to predict PE risk in terms of IRS according to variations in personal cfRNA profiling in early pregnancy (Figure 1A). For the first step, standardized and cleaned cfRNA sequencing data from normal pregnancy (NP) and PE were downloaded from GSE1929025 in Gene Expression Omnibus, which were collected ≤12 gestational weeks (gws) or at 13–20 gws. A total of 7160 detected cfRNAs were filtered to select cfRNAs with significant changes that could be used as indicators of PE risk. As illustrated in Figure 1B, we used multiple tests to optimize the parameters of the algorithm, a total of 29 cfRNAs were chosen as PE indicators for samples sequenced at ≤12 gws, and 25 cfRNAs were selected as samples sequenced at 13–20 gws (Table S1). In fact, only one clinical diagnosis conclusion was available for any enrolled woman: NP or PE. Therefore, we define that women in the PE group have the maximum IRS = 1 and NP have minimum IRS = 0. Based on the sequencing cfRNA from enrolled women, we can calculate their IRS using Equations (2) and (3). Next, we calculated the IRS at that sampling time. Calculated IRS is regarded as the ground truth for the enrolled women. At a sampling time ≤12 gws, the average of calculated IRS was 0.27 and 0.47 in NP and PE group, respectively (Figure 1C). At a sampling time of 13–20 gws, the average calculated IRS of NP and PE was 0.39 and 0.57, respectively (Figure 1D). The average calculated IRS for the NP group differed notably from that of the PE group (Supplementary Figure 1). The results suggest that the filtered cfRNA indicators work well to distinguish NP from PE and support the application of the proposed model in clinical practice. Next, we used an FCDN model to perform data regression (Figure 1E). The procedure of FCDN on PE prediction is shown in Figure 1F. In the current study, different datasets were used for model training and validation. The dataset in GSE192902 was divided into Discover Cohort, Validation 1 Cohort and Validation 2 Cohort. For model training, Validation 2 Cohort (87 sets of real-world cfRNA profiles) and 7913 computer-generated cfRNA profiles were employed. For model validation, 1000 computer-generated cfRNA profiles were employed. For the final model validation (application), we used Discover Cohort, and Validation 1 Cohort, which include 215 sets of real-world cfRNA profiles. A more detailed method for FCND construction, training and validation is shown in the Supporting Information. Through FCDN model training and validation (Figure 2A,B), the loss value (mean absolute error [MAE]) of the probability prediction decreased to 0.027, and an optimized model could then be obtained. To validate the prediction accuracy of the model, we used cfRNA expression from the real world5 as the input set x_test for the FCDN model to obtain the FCDN-based IRS. Furthermore, the FCDN-based IRS was compared with the ground truth (calculated IRS) calculated from real-world cfRNA profiling. At a sampling time of ≤12 gws, the tendency and amplitude of the FCDN-based IRS (prediction results) resembled the ground truth, suggesting the fitting ability of our FCDN model (Figure 2C). The MAE between the prediction result and the ground truth was only 0.032. PE and NP can be separated using averaged FCDN-based IRS. We also calculated the FCDN-based IRS for samples enrolled 13–20 gws (Figure 2D). Over the whole scale, the prediction results approximate the ground truth. The MAE between the prediction result and ground truth was only 0.041, indicating that the FCDN model predicted the ground truth well. The error amplitude of the FCDN-based IRS in processing cfRNA samples ≤12 gws is shown in Figure 2E. The maximum value of the absolute error, the peak-to-valley (PV) value of the error, and the mean value of the absolute error were 0.12, 0.16 and 0.046, respectively. For samples within 13−20 gws (Figure 2F), the maximum value of the absolute error reached 0.16, and the PV value of the error reached 0.27. The mean absolute error was 0.008. In short, the prediction error for IRS was well-controlled within a small amplitude, and the FCDN model was able to fit the data well. We also considered processing efficiency when dealing with numerous datasets collected from population screening. Therefore, the prediction time efficiency was also used as another benchmark to evaluate the method. In this test, the cfRNA profiling samples were fed into the trained FCDN model, and the time required to output an IRS value was recorded. As shown in Figure 2G,H, the results of 15 consecutive experiments showed that the average time required to output an IRS reached 10−5 s per sample. In summary, we employed novel biomarker cfRNAs and an FCDN model to output an IRS to predict PE. The prediction accuracy and computational time of the proposed model reached 0.95 and 10−5 s per sample, respectively. The reported method provides a reliable tool for rapid and minimally invasive monitoring of individual PE risk and sheds new light on maternal and neonatal healthcare (Figure 3). We thank Mira N. Moufarrej, Sevahn K. Vorperian, Ronald J. Wong, Ana A. Campos, Cecele C. Quaintance, Rene V. Sit, Michelle Tan, Angela M. Detweiler, Honey Mekonen, Norma F. Neff, Courtney Baruch-Gravett, James A. Litch, Maurice L. Druzin, Virginia D. Winn, Gary M. Shaw, David K. Stevenson, and Stephen R. Quake for their illuminating research and their great effort in samples collecting and cfRNA sequencing. We also thanked Mr Tao Liu (Guangzhou Gene Denovo Biotechnology Co., Ltd.) for his kind help in bioinformatics analysis. Besides, we express our sincere thanks to all the enrolled participants again for their contribution to medical research. The authors declare no conflict of interest. This work was supported by the National Natural Science Foundation of China (82071670 and 81771616) to Jinjun Liu, Natural Science Foundation of Shaanxi Province (2023-JC-QN-0954) to Zheng Wang, Funding of Clinical Research Center of Shaanxi Province for Dental and Maxillofacial Diseases (2022YHJB08) to Xia Xiao and Jilin Science and Technology Development Project No. 20210502028ZP. Codes and scripts developed for this study are available upon reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Early characterisation and prediction of liver diseases in pregnancy by plasma cell-free RNAs.

Unique Microrna Expression Profiles in Plasmic Exosomes from Intrahepatic Cholestasis of Pregnancy

Immune Dysfunction Mediated by the Cerna Regulatory Network in Human Placenta Tissue of Intrahepatic Cholestasis Pregnancy.

Cell-free RNA and fully convolutional dense network-based early preeclampsia prediction.

LC-MS/MS untargeted lipidomics uncovers placenta lipid signatures from intrahepatic cholestasis of pregnancy

Non-invasive preeclampsia prediction using plasma cell-free RNA signatures

Placental Proteome Alterations in Women with Intrahepatic Cholestasis of Pregnancy.

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Noninvasive Preeclampsia Prediction Using Plasma Cell-Free RNA Signatures

Altered gene profile of placenta from women with intrahepatic cholestasis of pregnancy

Comprehensive Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Transcriptional Signatures of Macrophages in Intrahepatic Cholestasis of Pregnancy

Core biomarkers analysis benefit for diagnosis on human intrahepatic cholestasis of pregnancy

Serum Exosomes MicroRNAs Are Novel Non-Invasive Biomarkers of Intrahepatic Cholestasis of Pregnancy

Studies on Novel Diagnostic and Predictive Biomarkers of Intrahepatic Cholestasis of Pregnancy Through Metabolomics and Proteomics

Single-cell RNA sequencing reveals heterogeneity and differential expression of the maternal–fetal interface during ICP and normal pregnancy

Comprehensive Analysis of Quantitative Proteomics With DIA Mass Spectrometry and ceRNA Network in Intrahepatic Cholestasis of Pregnancy

Identification of two novel pathogenic variants of the NR1H4 gene in intrahepatic cholestasis of pregnancy patients

Placental Gene-Expression Profiles of Intrahepatic Cholestasis of Pregnancy Reveal Involvement of Multiple Molecular Pathways in Blood Vessel Formation and Inflammation

Diagnostic and Prognostic Value of Long Noncoding RNAs As Potential Novel Biomarkers in Intrahepatic Cholestasis of Pregnancy

Proteomic Biomarkers of Intrahepatic Cholestasis of Pregnancy

Early prediction of preeclampsia in pregnancy with cell-free RNA